ArticleJCI insight2018
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.
Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review.International journal of nanomedicine · 2022Pooled it
- Recent advances in diagnostic technologies for postoperative central nervous system infections: a review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Circulating Markers of Necroptosis in Acute Pancreatitis.Digestive diseases and sciences · 2024Article
- Drug-tolerant persister cells in cancer: the cutting edges and future directions.Nature reviews. Clinical oncology · 2023Review
- Cottonseed oil alleviates ischemic stroke injury by inhibiting ferroptosis.Brain and behavior · 2023Article
- Article
- Article
- Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.The Journal of experimental medicine · 2022Article
- Fully Automated Macro- and Microfluidic Production of [Molecules (Basel, Switzerland) · 2022Article
- Altered Elemental Distribution in Male Rat Brain Tissue as a Predictor of Glioblastoma Multiforme Growth-Studies Using SR-XRF Microscopy.International journal of molecular sciences · 2022Article
- Ascorbate Preferentially Stimulates Gallium-67 Uptake in Glioblastoma Cells.Journal of nuclear medicine & radiation therapy · 2022Article
- i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability.Computational and structural biotechnology journal · 2022Article
- Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- HyperpolarizedNMR in biomedicine · 2021Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- An Iron Metabolism-Related Gene Signature for the Prognosis of Colon Cancer.Frontiers in cell and developmental biology · 2021Article
- Multiparameter quantitative histological MRI values in high-grade gliomas: a potential biomarker of tumor progression.Neuro-oncology practice · 2020Article
- An Iron Metabolism-RelatedOncoTargets and therapy · 2020Article
- Homeostatic iron regulatory protein drives glioblastoma growth via tumor cell-intrinsic and sex-specific responses.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
Noninvasive tools that target tumor cells could improve the management of glioma. Cancer generally has a high demand for Fe(III), an essential nutrient for a variety of biochemical processes. We tested whether 68Ga-citrate, an Fe(III) biomimetic that binds to apo-transferrin in blood, detects glioma in preclinical models and patients using hybrid PET/MRI. Mouse PET/CT studies showed that 68Ga-citrate accumulates in subcutaneous U87MG xenografts in a transferrin receptor-dependent fashion within 4 hours after injection. Seventeen patients with WHO grade III or IV glioma received 3.7-10.2 mCi 68Ga-citrate and were imaged with PET/MR 123-307 minutes after injection to establish that the radiotracer can localize to human tumors. Multiple contrast-enhancing lesions were PET avid, and tumor to adjacent normal white matter ratios were consistently greater than 10:1. Several contrast-enhancing lesions were not PET avid. One minimally enhancing lesion and another tumor with significantly reduced enhancement following bevacizumab therapy were PET avid. Advanced MR imaging analysis of one patient with contrast-enhancing glioblastoma showed that metabolic hallmarks of viable tumor spatially overlaid with 68Ga-citrate accumulation. These early data underscore that high-grade glioma may be detectable with a radiotracer that targets Fe(III) transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.